A Phase I Clinical Study of 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma
The Phase I clinical trial of CAR-GPC3 T cells, sponsored by Zhejiang University, targets advanced hepatocellular carcinoma (HCC) patients who are not suitable for surgery or have progressed after standard therapies. This innovative approach leverages a 4th generation CAR-T cell technology, which may provide a competitive edge in the CAR-T landscape, particularly in solid tumors like HCC. The market for HCC therapies is expanding, driven by rising incidence rates and the need for effective treatments in advanced stages. The trial's completion suggests readiness for further development, potentially attracting interest from pharmaceutical partners or investors. The collaboration with CARsgen Therapeutics Co., Ltd. indicates a strategic industry partnership that may enhance commercialization prospects.
Indication: Advanced Hepatocellular Carcinoma
Modality: small molecule
Target: Glypican-3 (GPC3)
Sponsor: Zhejiang University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Glypican-3 (GPC3)
View original source fields
Condition raw: Advanced Hepatocellular Carcinoma
Condition normalized: Advanced Hepatocellular Carcinoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Glypican-3 (GPC3)
Target normalized: Glypican-3 (GPC3)